Stocks · News reference

LUCID CAPITAL MARKETS Initiates Coverage On Insight Molecular with Buy Rating, Announces Price Target of $8

Aug 24, 2026, 2:50 PMBenzinga Newsdesk

LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Insight Molecular (NASDAQ:IMDX) with a Buy rating and announces Price Target of $8.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 24, 2026, 10:34 AMBenzinga Insights
Transcript: Insight Molecular Q2 2026 Earnings Conference Call
Insight Molecular (NASDAQ:IMDX) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts
Read original at benzinga
IMDX
BenzingaAug 18, 2026, 10:30 AMBenzinga Newsdesk
Needham Reiterates Buy on Insight Molecular, Maintains $9 Price Target
Needham analyst Mike Matson reiterates Insight Molecular (NASDAQ:IMDX) with a Buy and maintains $9 price target.
Read original at benzinga
IMDX
BenzingaAug 11, 2026, 8:17 PMBenzinga Newsdesk
Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform Leveraging Digital PCR Technology For Reliable dd-cfDNA Results In Transplanted Organ Health Monitoring
Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at 11AM ET featuring Max Jacob Liebo, MD (Loyola
Read original at benzinga
IMDX